Treatment of Resistant Herpes Simplex Virus With Continuous-Infusion Acyclovir

Jeffrey P. Engel, Janet A. Englund, Courtney V. Fletcher, Edgar L. Hill

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Two patients with acquired immunodeficiency syndrome who developed severe ulcerative proctitis caused by herpes simplex virus type 2 that was resistant to acyclovir were successfully treated with 6 weeks of high-dose, continuousinfusion acyclovir sodium (1.5 to 2.0 mg/kg per hour). Viruses cultured from the lesions were resistant to acyclovir in vitro after the patients had received prolonged therapy with oral and intravenous acyclovir in traditional divided doses. Investigation into the mechanism of the acyclovir resistance revealed changes in the thymidine-kinase activity of both isolates. This viral enzyme phosphorylates acyclovir and is necessary for drug activation. The first patient’s isolate was deficient of all thymidine-kinase activity, while the second patient’s isolate had a thymidine kinase with altered substrate specificity for acyclovir. The continuous infusion was safe, well tolerated, and done in an outpatient setting with weekly clinic visits and monitoring of creatinine and acyclovir levels.

Original languageEnglish (US)
Pages (from-to)1662-1664
Number of pages3
JournalJAMA: The Journal of the American Medical Association
Volume263
Issue number12
DOIs
StatePublished - Mar 23 1990

Fingerprint

Acyclovir
Simplexvirus
Thymidine Kinase
Therapeutics
Proctitis
Human Herpesvirus 2
Ambulatory Care
Substrate Specificity
Creatinine
Acquired Immunodeficiency Syndrome
Outpatients
Viruses
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of Resistant Herpes Simplex Virus With Continuous-Infusion Acyclovir. / Engel, Jeffrey P.; Englund, Janet A.; Fletcher, Courtney V.; Hill, Edgar L.

In: JAMA: The Journal of the American Medical Association, Vol. 263, No. 12, 23.03.1990, p. 1662-1664.

Research output: Contribution to journalArticle

Engel, Jeffrey P. ; Englund, Janet A. ; Fletcher, Courtney V. ; Hill, Edgar L. / Treatment of Resistant Herpes Simplex Virus With Continuous-Infusion Acyclovir. In: JAMA: The Journal of the American Medical Association. 1990 ; Vol. 263, No. 12. pp. 1662-1664.
@article{54f74d0b90e24b8d9812e1da16a85659,
title = "Treatment of Resistant Herpes Simplex Virus With Continuous-Infusion Acyclovir",
abstract = "Two patients with acquired immunodeficiency syndrome who developed severe ulcerative proctitis caused by herpes simplex virus type 2 that was resistant to acyclovir were successfully treated with 6 weeks of high-dose, continuousinfusion acyclovir sodium (1.5 to 2.0 mg/kg per hour). Viruses cultured from the lesions were resistant to acyclovir in vitro after the patients had received prolonged therapy with oral and intravenous acyclovir in traditional divided doses. Investigation into the mechanism of the acyclovir resistance revealed changes in the thymidine-kinase activity of both isolates. This viral enzyme phosphorylates acyclovir and is necessary for drug activation. The first patient’s isolate was deficient of all thymidine-kinase activity, while the second patient’s isolate had a thymidine kinase with altered substrate specificity for acyclovir. The continuous infusion was safe, well tolerated, and done in an outpatient setting with weekly clinic visits and monitoring of creatinine and acyclovir levels.",
author = "Engel, {Jeffrey P.} and Englund, {Janet A.} and Fletcher, {Courtney V.} and Hill, {Edgar L.}",
year = "1990",
month = "3",
day = "23",
doi = "10.1001/jama.1990.03440120084042",
language = "English (US)",
volume = "263",
pages = "1662--1664",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Treatment of Resistant Herpes Simplex Virus With Continuous-Infusion Acyclovir

AU - Engel, Jeffrey P.

AU - Englund, Janet A.

AU - Fletcher, Courtney V.

AU - Hill, Edgar L.

PY - 1990/3/23

Y1 - 1990/3/23

N2 - Two patients with acquired immunodeficiency syndrome who developed severe ulcerative proctitis caused by herpes simplex virus type 2 that was resistant to acyclovir were successfully treated with 6 weeks of high-dose, continuousinfusion acyclovir sodium (1.5 to 2.0 mg/kg per hour). Viruses cultured from the lesions were resistant to acyclovir in vitro after the patients had received prolonged therapy with oral and intravenous acyclovir in traditional divided doses. Investigation into the mechanism of the acyclovir resistance revealed changes in the thymidine-kinase activity of both isolates. This viral enzyme phosphorylates acyclovir and is necessary for drug activation. The first patient’s isolate was deficient of all thymidine-kinase activity, while the second patient’s isolate had a thymidine kinase with altered substrate specificity for acyclovir. The continuous infusion was safe, well tolerated, and done in an outpatient setting with weekly clinic visits and monitoring of creatinine and acyclovir levels.

AB - Two patients with acquired immunodeficiency syndrome who developed severe ulcerative proctitis caused by herpes simplex virus type 2 that was resistant to acyclovir were successfully treated with 6 weeks of high-dose, continuousinfusion acyclovir sodium (1.5 to 2.0 mg/kg per hour). Viruses cultured from the lesions were resistant to acyclovir in vitro after the patients had received prolonged therapy with oral and intravenous acyclovir in traditional divided doses. Investigation into the mechanism of the acyclovir resistance revealed changes in the thymidine-kinase activity of both isolates. This viral enzyme phosphorylates acyclovir and is necessary for drug activation. The first patient’s isolate was deficient of all thymidine-kinase activity, while the second patient’s isolate had a thymidine kinase with altered substrate specificity for acyclovir. The continuous infusion was safe, well tolerated, and done in an outpatient setting with weekly clinic visits and monitoring of creatinine and acyclovir levels.

UR - http://www.scopus.com/inward/record.url?scp=0025268266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025268266&partnerID=8YFLogxK

U2 - 10.1001/jama.1990.03440120084042

DO - 10.1001/jama.1990.03440120084042

M3 - Article

C2 - 2308204

AN - SCOPUS:0025268266

VL - 263

SP - 1662

EP - 1664

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 12

ER -